<DOC>
	<DOCNO>NCT01474720</DOCNO>
	<brief_summary>Individuals systemic lupus erythematosus ( SLE , lupus ) appear increase risk development shingle , painful reactivation varicella zoster virus cause chicken pox . The investigator propose study immune response commercially available Zostavax vaccine ( shingle vaccine ) adult patient SLE minimal disease activity mild immunosuppressant medication , compare immune response see healthy people follow vaccination . Acceptable immunosuppressive drug permit study felt safe accord Centers Disease Control guideline . Ten healthy people 10 SLE patient ( 50 year age ) recruit receive single , standard dose Zostavax . Blood sample physical examination perform prior injection , 2,6 , 12 week follow vaccination . All participant receive active vaccine , placebo group .</brief_summary>
	<brief_title>Zostavax Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥ 50 year Willing able provide write informed consent History primary varicella vaccination positive VZV IgG antibodies Diagnosis SLE accord ACR criterion &gt; 1 year ; healthy control subject Stable , mild disease activity define clinical SLEDAI score ≤ 4 Current medical treatment SLE stable 4 week prior screen Acceptable immunosuppressive medication limit Prednisone ≤ 10 mg daily Methotrexate ≤ 20 mg weekly Azathioprine ≤ 150 mg daily Hydroxychloroquine ≤ 6.5 mg/kg daily Female subject childbearing potential nonsterile male must agree use acceptable form contraception duration study History receive VZVcontaining vaccine ( primary varicella zoster ) History herpes zoster reactivation within 5 year prior enrollment Received live vaccine within 6 week inactivated/recombinant vaccine within 2 week enrollment Known Hepatitis B , C HIV virus infection History drug alcohol abuse within 1 year screen Rituximab therapy within 2 year screen Cyclophosphamide within 6 month screen Biologic therapy ( TNF inhibitor , CTLA4Ig , etc . ) within 6 month screen Use mycophenolate mofetil within 3 month screen History receive immunoglobulin blood product within 3 month screen Allergic reaction , intolerance contraindication use famciclovir . Has receive experimental/investigational agent ( vaccine , drug , biologic , device , blood product , medication ) within 3 month screen ; expect receive another experimental/investigational agent within 6 month post immunization . Pregnant lactate woman Unwilling use acceptable method contraception duration study WBC &lt; 3.0 ; ANC &lt; 1500 ; CD4+ &lt; 200 Proteinuria &gt; 1.5 mg/day Impaired renal function define serum Cr &gt; 1.5 Transaminases &gt; 2x upper limit normal Clinical SLEDAI &gt; 4 Active lupus nephritis cerebritis History neoplastic disease within 5 year screen , except completely excise nonmelanoma cancer skin insitu carcinoma uterine cervix . History hematological malignancy , current bleeding disorder take anticoagulant medication ( heparin warfarin ) . Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol . Has moderate severe acute illness and/or oral temperature great equal 100.0oF , within 72 hour prior vaccination ( may result temporary delay vaccination ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>Zostavax</keyword>
	<keyword>shingle</keyword>
</DOC>